ArticleiScience2026
ReliST: A model-agnostic risk layer for spatial transcriptomics deconvolution.
Article in iScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Spatial transcriptomics deconvolution maps cell-type abundance across tissue, but most outputs do not indicate which local predictions can be trusted. We developed ReliST, a model-agnostic risk layer that preserves base predictions while assigning spot-level risk from output ambiguity, local inconsistency, and reference-related evidence. We evaluated ReliST with five deconvolution models across human dorsolateral prefrontal cortex (DLPFC), mouse brain, human breast cancer, and an independent immunofluorescence/gene-protein dataset. In DLPFC, risk scores aligned with layer difficulty, marker discordance, and signature residuals. In mouse brain, ReliST provided reference-control and review signals without layer labels. In breast cancer, high-risk regions aligned with histology context, stromal and vascular shifts, immune-associated protein evidence, and abundance-adjusted protein residuals consistent with protein-supported under-calls. ReliST extends spatial deconvolution from prediction-only maps to risk-aware interpretation, supporting filtering, abstention, and targeted review rather than universal model ranking or spot-level truth assignment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.